BVS Bioventus

Dave Crawford Joins Bioventus as Vice President, Investor Relations and Treasurer

Dave Crawford Joins Bioventus as Vice President, Investor Relations and Treasurer

DURHAM, N.C., Aug. 23, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has appointed Dave Crawford as its Vice President, Investor Relations and Treasurer. Crawford has more than 20 years of experience across multiple areas of finance and comes to Bioventus from Avanos Medical, Inc. where he served for nearly seven years as its Vice President Treasurer, Investor Relations and Financial Planning and Analysis.

“We are happy to welcome Dave to lead our investor relations department and manage treasury at Bioventus,” said Greg Anglum, Senior Vice President and CFO. “Dave’s record of accomplishments, strong relationships within the financial community and career in finance and treasury are a perfect fit for the Company.”

Previously, Crawford spent several years in finance and treasury roles with Kimberly-Clark Corporation and was later promoted to Chief Financial Officer of the company’s Global Healthcare Division. Prior to that, Crawford held financial and treasury roles with Eli Lilly & Company. He began his career as a tax consultant with Arthur Andersen.

Crawford has an MBA from Duke University and received a Bachelor of Business Administration in Accounting from the University of Notre Dame.



About Bioventus

Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for pain treatment & joint preservation, restorative therapies and bone graft substitutes. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit , and follow the Company on and .



Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

Media Contact:

Thomas Hill

Bioventus

919-474-6715

Investor Inquiries:

Mike Piccinino, CFA, IRC

Westwicke/ICR



EN
23/08/2021

Underlying

BVSBioventus

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioventus

 PRESS RELEASE
Free
BVS BIOVENTUS

Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Resul...

Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026 DURHAM, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- , a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2025 before the market opens on Thursday, March 5, 2026. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call....

February 24, 2026 1 EN
 PRESS RELEASE
Free
BVS BIOVENTUS

Bioventus to Present at the 44th Annual J.P. Morgan Healthcare Confere...

Bioventus to Present at the 44th Annual J.P. Morgan Healthcare Conference DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 9:45 a.m. PT (12:45 p.m. ET). The live webcast of the presentation, including Q&A, may be accessed on the Investors section of the Bioventus website and will be available for replay until February 14, 2026. About BioventusBioventus delivers c...

January 6, 2026 1 EN
 PRESS RELEASE
Free
BVS BIOVENTUS

Bioventus to Present at the Piper Sandler 37th Annual Healthcare Confe...

Bioventus to Present at the Piper Sandler 37th Annual Healthcare Conference DURHAM, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will present at the Piper Sandler Healthcare Conference on Wednesday, December 3, 2025, at 10:10 a.m. ET. A live webcast of the presentation, followed by a question-and-answer session will be available on the “Investors” section of the Company’s website at and will be available for replay on that site following the ...

November 25, 2025 1 EN
 PRESS RELEASE
Free
BVS BIOVENTUS

Bioventus Reports Third Quarter Financial Results

Bioventus Reports Third Quarter Financial Results Q3 reported revenue of $138.7 million was comparable to last year and organic* revenue advanced 8%Third quarter GAAP earnings of $0.05 per diluted share increased compared to the prior-year period loss of $0.08 per diluted shareNon-GAAP earnings* of $0.15 per diluted share increased 200%Cash from operations of $30.1 million increased 192%Company reaffirms revenue, Adjusted EBITDA* and Non-GAAP EPS* guidance for full year 2025 DURHAM, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) --  Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a ...

November 4, 2025 1 EN
 PRESS RELEASE
Free
BVS BIOVENTUS

Bioventus to Report Third Quarter of Fiscal Year 2025 Financial Result...

Bioventus to Report Third Quarter of Fiscal Year 2025 Financial Results on November 4, 2025 DURHAM, N.C., Oct. 28, 2025 (GLOBE NEWSWIRE) -- a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2025 before the market opens on Tuesday, November 4, 2025. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Cal...

October 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch